(NRC) National Research - Ratings and Ratios

Exchange: NASDAQ • Country: United States • Currency: USD • Type: Common Stock • ISIN: US6373722023

NRC: Patient Experience, Employee Engagement, Reputation Management, Governance Solutions, Marketing Analytics

National Research Corporation (NASDAQ:NRC) specializes in delivering data-driven insights to enhance patient and employee experiences within the healthcare sector. Through its subscription-based platform, the company provides actionable analytics across critical areas such as patient satisfaction, service recovery, care transitions, and employee engagement. These tools enable healthcare organizations to identify gaps, improve operational efficiency, and align with patient and staff expectations.

The companys marketing solutions include brand tracking, competitive benchmarking, and advanced segmentation tools to analyze community needs and behaviors. This allows healthcare providers to refine their branding strategies and maintain a strong market presence. Additionally, NRC offers reputation management solutions that help organizations showcase their strengths and ensure consistent, relevant messaging to influence consumer decisions.

National Research Corporation also provides governance solutions tailored for not-for-profit healthcare boards, executives, and physician leaders. These tools support informed decision-making and strategic planning. Founded in 1981 and headquartered in Lincoln, Nebraska, the company has established itself as a key player in healthcare analytics, serving organizations across the U.S. with a focus on improving experiences and operational outcomes.

Ticker Symbol: NRC Exchange: NASDAQ Type: common stock Country Origin: United States GICS Sub Industry: Health Care Services

3-Month Forecast: Based on and , NRC is expected to face headwinds due to the bearish crossover of its SMA 20 and SMA 50, currently at 16.45 and 17.00 respectively, below the last price of 14.59. The ATR of 0.80 suggests moderate volatility. However, strong fundamentals, including a P/E of 15.01 and RoE of 78.21, may provide support. The stock is likely to test lower support levels but could stabilize if operational performance remains robust.

Additional Sources for NRC Stock

NRC Stock Overview

Market Cap in USD 342m
Sector Healthcare
Industry Health Information Services
GiC Sub-Industry Health Care Services
IPO / Inception 1997-10-10

NRC Stock Ratings

Growth 5y -78.5%
Fundamental 31.7%
Dividend 44.0%
Rel. Strength Industry -62.2
Analysts 4/5
Fair Price Momentum 11.25 USD
Fair Price DCF 20.87 USD

NRC Dividends

Dividend Yield 12m 2.65%
Yield on Cost 5y 1.44%
Annual Growth 5y 17.98%
Payout Consistency 73.1%

NRC Growth Ratios

Growth Correlation 3m -71.4%
Growth Correlation 12m -97.3%
Growth Correlation 5y -74.1%
CAGR 5y -14.94%
CAGR/Max DD 5y -0.20
Sharpe Ratio 12m -0.97
Alpha -72.02
Beta 0.92
Volatility 35.92%
Current Volume 76.5k
Average Volume 20d 78.7k
What is the price of NRC stocks?
As of March 15, 2025, the stock is trading at USD 14.83 with a total of 76,541 shares traded.
Over the past week, the price has changed by -1.85%, over one month by -16.21%, over three months by -13.15% and over the past year by -61.85%.
Is National Research a good stock to buy?
Neither. Based on ValueRay Fundamental Analyses, National Research is currently (March 2025) neither a good nor a bad stock to buy. It has a ValueRay Fundamental Rating of 31.67 and therefor a neutral outlook according to the companies health.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of NRC as of March 2025 is 11.25. This means that NRC is currently overvalued and has a potential downside of -24.14%.
Is NRC a buy, sell or hold?
National Research has received a consensus analysts rating of 4.00. Therefor, it is recommend to buy NRC.
  • Strong Buy: 0
  • Buy: 1
  • Hold: 0
  • Sell: 0
  • Strong Sell: 0
What are the forecast for NRC stock price target?
According to ValueRays Forecast Model, NRC National Research will be worth about 12.4 in March 2026. The stock is currently trading at 14.83. This means that the stock has a potential downside of -16.39%.
Issuer Forecast Upside
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 12.4 -16.4%